Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years and older
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:completedIn |
March 2015
|
| gptkbp:conditionStudied |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:enrollment |
582
|
| gptkbp:gender |
All
|
| gptkbp:intervention |
gptkb:Docetaxel
gptkb:Nivolumab |
| gptkbp:location |
gptkb:Europe
gptkb:United_States |
| gptkbp:mask |
None (Open Label)
|
| gptkbp:officialName |
A Study of Nivolumab (BMS-936558) Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (CheckMate 017)
|
| gptkbp:otherName |
CheckMate 017
|
| gptkbp:primaryCompletionDate |
March 2015
|
| gptkbp:recognizedBy |
gptkb:NCT02142738
|
| gptkbp:result |
Overall Survival
|
| gptkbp:sponsor |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:startDate |
June 2014
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:KEYNOTE-024
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT02142738
|